Industry Sponsored Symposia & Satellite CME Symposia - IASLC 2021 WCLC World Conference on Lung Cancer

To view the Industry Sponsored Symposia & Satellite CME Symposia , please select the destination that is closest to your time zone and then click on the arrows below to see more details for each session.

IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC

Date: Wednesday, September 8, 2021 | Time: 11:00 – 12:00 PDT

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne, MD, PhD (USA)
Suresh S. Ramalingam, MD (USA)
Solange Peters, MD, PhD, (Switzerland)

Agenda

Welcome and Introduction (5 min)
Pasi Jänne, MD, PhD, USA
Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC (15 min)
Suresh S. Ramalingam, MD, USA
Targeting Checkpoint Inhibitor Resistance in NSCLC (15 min)
Solange Peters, MD, PhD, Switzerland
Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-driven NSCLC (15 min)
Pasi Jänne, MD, PhD, USA
Q & A (10 min)

IS02 - Satellite CME Symposium by Med Learning Group: A New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View

Date: Wednesday, September 8, 2021 | Time: 11:00 – 12:00 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Charu Aggarwal, MD, MPH (USA)
Stephen Liu, MD (USA)

Agenda
Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer (15 min) Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC (15 min) Applying National Cancer Center Network (NCCN) Guidelines to Practice (15 min) Conclusions (5 min) Questions and Answers (10 min)

IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Date: Wednesday, September 8, 2021 | Time: 11:00 – 12:00 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Tony Mok, MD, FRCPC, FASCO (HK)
Shirish Gadgeel, MD (USA)
Antonio Passaro, MD, PhD (Italy)

Agenda
Welcome and Introductions (5 min) Prof. Tony S.K. Mok (Chair) EGFR Insertion Mutations in NSCLC: Why and How Do We Test? (15 min) Dr. Shirish M. Gadgeel New and Emerging Therapies for NSCLC with EXON 20 INS Mutations (20 min) Prof. Tony S.K. Mok (Chair) Managing Toxicity with Anti-EGFR Exon 20 Agents (10 min) Dr. Antonio Passaro Audience Q&A and Closing Remarks (10 min) All Faculty

IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs’

Date: Thursday, September 9, 2021 | Time: 04:15 - 05:15 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Yi-Long Wu, MD (China)
Suresh Senan, MRCP, FRCR, PhD (The Netherlands)
Zhijie Wang (China)

Agenda
Welcome and Introduction (5 min) Yi-Long Wu Clinical data with immuno-oncology for unresectable Stage III NSCLC (15 min) Suresh Senan Translating the clinical benefits of EGFR-TKIs across EGFRm NSCLC (15 min) Zhijie Wang Panel discussion: Survivorship in NSCLC (25 min) All/Panel(Chaired by Yi-Long Wu)

IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape With Novel Strategies

Date: Thursday, September 9, 2021 | Time: 12:15 - 13:15 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

David R. Gandara (USA)
Alexander I Spira, MD, PhD, FACP (USA)
Afshin N. Dowlati, MD (USA)

Agenda
Welcome and Introductions (5 min) David R. Gandara The Evolving Biomarker Landscape in Advanced NSCLC (15 min) David R. Gandara KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC (15 min) Alexander I. Spira Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC (15 min) Afshin Dowlati Discussion All Faculty

IS06 - Industry Symposium Sponsored by Jazz Pharmaceuticals: Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC)

Date: Thursday, September 9, 2021 | Time: 12:15 - 13:15 PDT

View Program / Invitation (PDF)

Speaker:

Eric Nadler, MD, MPP (USA)

Agenda
An overview of unmet needs in SCLC Eric Nadler Current treatment guidelines for SCLC Eric Nadler Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Eric Nadler Considerations for dosing, administration, and patient counseling Eric Nadler

IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Date: Thursday, September 9, 2021 | Time: 12:15 - 13:15 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Roy Herbst, MD, PhD (USA)
Sarah Goldberg, MD, MPH (USA)
Aleš Ryška, MUDr, PhD (Czech Republic)

Agenda
Introduction (5 min) Roy Herbst, MD, PhD, USA Key Concepts in NSCLC Biomarker Testing (15 min) Aleš Ryška, MUDr, PhD, Czech Republic Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC (20 min) Roy Herbst, MD, PhD, USA IRAE Considerations for Patients with NSCLC Receiving Immunotherapy (10 min) Sarah Goldberg, MD, MPH, USA Q&A Session (10 min)

IS08 - Industry Symposium Sponsored by Eli Lilly And Company: Personalizing and Optimizing Treatment for Metastatic NSCLC patients with EGFR Mutations - Is there more we can do?

Date: Friday, September 10, 2021 | Time: 04:45 – 05:45 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Mark Socinski, MD (USA)
Silvia Novello, MD, PhD (Italy)
Nobuyuki Takakura, MD, PhD (Japan)
Myung- Ju Ahn, MD (South Korea)

Agenda

Welcome and introduction (5 min)
Chair – Mark Socinski, USA
Is a one size fits all approach still appropriate for NSCLC with an EGFR mutation, are all mutations equal? (15 min)
Silvia Novello, Italy
Scientific rationale for dual inhibition of VEGF and EGFR (10 min)
Nobuyuki Takakura, Japan
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (10 min)
Myung-Ju Ahn, Korea
Panel discussion and Q&A (15 min)
Symposium closing remarks (5 min)
Chair – Mark Socinski, USA

IS09 - Industry Symposium Sponsored by Janssen Pharmaceutical Research & Development: Innovations in Lung Cancer Detection and Management of Non-Small Cell Lung Cancer (NSCLC) With Targeted Therapy

Date: Friday, September 10, 2021 | Time: 04:45 – 05:45 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Joshua Sabari, MD (USA)
Ticiana A. Leal, MD (USA)
Chris Manley, MD (USA)

Agenda
Welcome and introductions Joshua Sabari, MD (USA) EGFR mutated NSCLC – Progress, Recent Developments, and Unmet Needs Ticiana A. Leal, MD, USA Advances in early diagnosis, detection and intervention of lung cancer Chris Manley, MD, USA Discussion/Q&A

IS10 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer and Validated Targets Beyond EGFR

Date: Friday, September 10, 2021 | Time: 04:45 – 05:45 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

D Ross Camidge, MD, PhD (USA)
Justin F Gainor, MD (USA)
Alexander E Drilon, MD (USA)
Neil Love, MD (USA)

Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?

Date: Sunday, September 12, 2021 | Time: 20:15 – 21:15 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Zofia Piotrowska, MD (USA)
Joshua Sabari, MD (USA)
Maureen Zakowski, MD, JD (USA)

Agenda
Introduction Zofia Piotrowska, MD Key Questions for Practice: Optimizing the Diagnosis and Management of Patients With NSCLC and Molecular Alterations Zofia Piotrowska, MD Joshua Sabari, MD Maureen Zakowski, MD, JD Conclusions and Q&A Zofia Piotrowska, MD Backstage Pass Breakout Session (Optional)

IS12 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Early-Stage Non-Small Cell Lung Cancer

Date: Sunday, September 12, 2021 | Time: 20:15 – 21:15 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Edward B Garon, MD, MS (USA)
Harvey I Pass, MD (USA)
Heather Wakelee, MD (USA)
Neil Love, MD (USA)

Agenda
Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

Date: Monday, September 13, 2021 | Time: 15:15 – 16:15 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Luis Paz-Ares, MD, PhD (Spain)
Corey Langer, MD (USA)
Keunchil Park, MD PhD (South Korea)
Marina Garassino, MBBS (Italy)

Agenda
Disease Landscape Overview (15 min) Luis Paz-Ares, MD, PhD, Spain Pathobiology and Molecular Profile of ADC targets in NSCLC (10 min) Corey Langer, MD, USA ADCs Targeting the HER Family and Clinical Data in NSCLC (10 min) Keunchil Park, MD PhD, South Korea Emerging ADC Targets and Clinical Data in NSCLC (10 min) Marina Garassino, MBBS, Italy Faculty Panel: Live Q&A (15 min)

IS15 - Satellite CME Symposium by Clinical Care Options: Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

Date: Tuesday, September 14, 2021 | Time: 14:00 – 15:00 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Julie R. Brahmer, MD (USA)
Jarushka Naidoo, MB BCH BAO, MHS (USA)

Agenda

Welcome and Introduction (5 min)
Overview of Immunotherapy in Nonmetastatic NSCLC (15 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Current immunotherapy landscape in advanced NSCLC
• New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC (25 min)

Julie R. Brahmer, MD, USA

• Current immunotherapy landscape in advanced NSCLC

• Immune resistance and sequencing of therapy

• Emerging biomarkers of response to ICI therapy in NSCLC
Immunotherapy in Advanced or Metastatic NSCLC: Special Populations (10 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Response to ICI-based therapy in patients with cachexia
• ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation
Final Panel Discussion and Audience Question and Answer Session (5 min)

IS16 - Industry Symposium Sponsored by Exact Sciences: What Can We Learn from NSCLC? Using Comprehensive Genomic Profiling to Enhance Patient Care

Date: Tuesday, September 14, 2021 | Time: 14:00 – 15:00 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Edgardo Santos, MD, FACP (USA)
Snehal Thakkar, MD (USA)
Lisa Macera, PhD (USA)

Agenda
Welcome & Introduction (5 min) Edgardo Santos Growing Importance of Genomic Profiling (15 min) Snehal Thakkar Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection (15 min) Lisa Macera NSCLC Case Studies (15 min) Snehal Thakkar, Edgardo Santos Q&A (10 min) All Faculty

IS17 - Satellite CME Symposium by PeerView Institute for Medical Education: Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapy to Address Unmet Needs in Advanced NSCLC

Date: Tuesday, September 14, 2021 | Time: 14:00 – 15:00 PDT

View Program / Invitation (PDF)

Chairs/Speakers:

Melissa L. Johnson, MD (USA)
Helena Yu, MD (USA)
Benjamin Levy, MD (USA)

Agenda

Welcome and Introduction
MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient

Clinical Accelerator: Translating Science, Transforming Practice

• Profiles of New and Emerging HER2-, HER3-, and TROP2-Targeting Agents in NSCLC

• Delving Into the Data: Expert Discussions on the Latest Findings on HER2-, HER3-, and TROP2-Targeted Therapies
• Expert Perspectives on the Clinical Implications and Potential of Investigational Targeted Agents to Transform the Treatment of HER2-, HER3-, and TROP2-Altered NSCLC

Synthesis and Conclusions

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne, MD, PhD (USA)
Suresh S. Ramalingam, MD (USA)
Solange Peters, MD, PhD, (Switzerland)

Agenda

Welcome and Introduction (5 min)
Pasi Jänne, MD, PhD, USA
Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC (15 min)
Suresh S. Ramalingam, MD, USA
Targeting Checkpoint Inhibitor Resistance in NSCLC (15 min)
Solange Peters, MD, PhD, Switzerland
Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-driven NSCLC (15 min)
Pasi Jänne, MD, PhD, USA
Q & A (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Charu Aggarwal, MD, MPH (USA)
Stephen Liu, MD (USA)

Agenda
Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer (15 min) Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC (15 min) Applying National Cancer Center Network (NCCN) Guidelines to Practice (15 min) Conclusions (5 min) Questions and Answers (10 min)

IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Date: Wednesday, September 8, 2021 | Time: 12:00 - 13:00 MDT

View Program / Invitation (PDF)

Chairs/Speakers:

Tony Mok, MD, FRCPC, FASCO (HK)
Shirish Gadgeel, MD (USA)
Antonio Passaro, MD, PhD (Italy)

Agenda
Welcome and Introductions (5 min) Prof. Tony S.K. Mok (Chair) EGFR Insertion Mutations in NSCLC: Why and How Do We Test? (15 min) Dr. Shirish M. Gadgeel New and Emerging Therapies for NSCLC with EXON 20 INS Mutations (20 min) Prof. Tony S.K. Mok (Chair) Managing Toxicity with Anti-EGFR Exon 20 Agents (10 min) Dr. Antonio Passaro Audience Q&A and Closing Remarks (10 min) All Faculty

IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs’

Date: Thursday, September 9, 2021 | Time: 05:15 - 06:15 MDT

View Program / Invitation (PDF)

Chairs/Speakers:

Yi-Long Wu, MD (China)
Suresh Senan, MRCP, FRCR, PhD (The Netherlands)
Zhijie Wang (China)

Agenda
Welcome and Introduction (5 min) Yi-Long Wu Clinical data with immuno-oncology for unresectable Stage III NSCLC (15 min) Suresh Senan Translating the clinical benefits of EGFR-TKIs across EGFRm NSCLC (15 min) Zhijie Wang Panel discussion: Survivorship in NSCLC (25 min) All/Panel(Chaired by Yi-Long Wu)

IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape With Novel Strategies

Date: Thursday, September 9, 2021 | Time: 13:15 - 14:15 MDT

View Program / Invitation (PDF)

Chairs/Speakers:

David R. Gandara (USA)
Alexander I Spira, MD, PhD, FACP (USA)
Afshin N. Dowlati, MD (USA)

Agenda
Welcome and Introductions (5 min) David R. Gandara The Evolving Biomarker Landscape in Advanced NSCLC (15 min) David R. Gandara KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC (15 min) Alexander I. Spira Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC (15 min) Afshin Dowlati Discussion All Faculty

View Program / Invitation (PDF)

Speaker:

Eric Nadler, MD, MPP (USA)

Agenda
An overview of unmet needs in SCLC Eric Nadler Current treatment guidelines for SCLC Eric Nadler Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Eric Nadler Considerations for dosing, administration, and patient counseling Eric Nadler

IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Date: Thursday, September 9, 2021 | Time: 13:15 - 14:15 MDT

View Program / Invitation (PDF)

Chairs/Speakers:

Roy Herbst, MD, PhD (USA)
Sarah Goldberg, MD, MPH (USA)
Aleš Ryška, MUDr, PhD (Czech Republic)

Agenda
Introduction (5 min) Roy Herbst, MD, PhD, USA Key Concepts in NSCLC Biomarker Testing (15 min) Aleš Ryška, MUDr, PhD, Czech Republic Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC (20 min) Roy Herbst, MD, PhD, USA IRAE Considerations for Patients with NSCLC Receiving Immunotherapy (10 min) Sarah Goldberg, MD, MPH, USA Q&A Session (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Mark Socinski, MD (USA)
Silvia Novello, MD, PhD (Italy)
Nobuyuki Takakura, MD, PhD (Japan)
Myung- Ju Ahn, MD (South Korea)

Agenda

Welcome and introduction (5 min)
Chair – Mark Socinski, USA
Is a one size fits all approach still appropriate for NSCLC with an EGFR mutation, are all mutations equal? (15 min)
Silvia Novello, Italy
Scientific rationale for dual inhibition of VEGF and EGFR (10 min)
Nobuyuki Takakura, Japan
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (10 min)
Myung-Ju Ahn, Korea
Panel discussion and Q&A (15 min)
Symposium closing remarks (5 min)
Chair – Mark Socinski, USA

View Program / Invitation (PDF)

Chairs/Speakers:

Joshua Sabari, MD (USA)
Ticiana A. Leal, MD (USA)
Chris Manley, MD (USA)

Agenda
Welcome and introductions Joshua Sabari, MD (USA) EGFR mutated NSCLC – Progress, Recent Developments, and Unmet Needs Ticiana A. Leal, MD, USA Advances in early diagnosis, detection and intervention of lung cancer Chris Manley, MD, USA Discussion/Q&A

View Program / Invitation (PDF)

Chairs/Speakers:

D Ross Camidge, MD, PhD (USA)
Justin F Gainor, MD (USA)
Alexander E Drilon, MD (USA)
Neil Love, MD (USA)

Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?

Date: Sunday, September 12, 2021 | Time: 21:15 – 22:15 MDT

View Program / Invitation (PDF)

Chairs/Speakers:

Zofia Piotrowska, MD (USA)
Joshua Sabari, MD (USA)
Maureen Zakowski, MD, JD (USA)

Agenda
Introduction Zofia Piotrowska, MD Key Questions for Practice: Optimizing the Diagnosis and Management of Patients With NSCLC and Molecular Alterations Zofia Piotrowska, MD Joshua Sabari, MD Maureen Zakowski, MD, JD Conclusions and Q&A Zofia Piotrowska, MD Backstage Pass Breakout Session (Optional)

View Program / Invitation (PDF)

Chairs/Speakers:

Edward B Garon, MD, MS (USA)
Harvey I Pass, MD (USA)
Heather Wakelee, MD (USA)
Neil Love, MD (USA)

Agenda
Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

Date: Monday, September 13, 2021 | Time: 16:15 – 17:15 MDT

View Program / Invitation (PDF)

Chairs/Speakers:

Luis Paz-Ares, MD, PhD (Spain)
Corey Langer, MD (USA)
Keunchil Park, MD PhD (South Korea)
Marina Garassino, MBBS (Italy)

Agenda
Disease Landscape Overview (15 min) Luis Paz-Ares, MD, PhD, Spain Pathobiology and Molecular Profile of ADC targets in NSCLC (10 min) Corey Langer, MD, USA ADCs Targeting the HER Family and Clinical Data in NSCLC (10 min) Keunchil Park, MD PhD, South Korea Emerging ADC Targets and Clinical Data in NSCLC (10 min) Marina Garassino, MBBS, Italy Faculty Panel: Live Q&A (15 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Julie R. Brahmer, MD (USA)
Jarushka Naidoo, MB BCH BAO, MHS (USA)

Agenda

Welcome and Introduction (5 min)
Overview of Immunotherapy in Nonmetastatic NSCLC (15 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Current immunotherapy landscape in advanced NSCLC
• New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC (25 min)

Julie R. Brahmer, MD, USA

• Current immunotherapy landscape in advanced NSCLC

• Immune resistance and sequencing of therapy

• Emerging biomarkers of response to ICI therapy in NSCLC
Immunotherapy in Advanced or Metastatic NSCLC: Special Populations (10 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Response to ICI-based therapy in patients with cachexia
• ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation
Final Panel Discussion and Audience Question and Answer Session (5 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Edgardo Santos, MD, FACP (USA)
Snehal Thakkar, MD (USA)
Lisa Macera, PhD (USA)

Agenda
Welcome & Introduction (5 min) Edgardo Santos Growing Importance of Genomic Profiling (15 min) Snehal Thakkar Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection (15 min) Lisa Macera NSCLC Case Studies (15 min) Snehal Thakkar, Edgardo Santos Q&A (10 min) All Faculty

View Program / Invitation (PDF)

Chairs/Speakers:

Melissa L. Johnson, MD (USA)
Helena Yu, MD (USA)
Benjamin Levy, MD (USA)

Agenda

Welcome and Introduction
MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient

Clinical Accelerator: Translating Science, Transforming Practice

• Profiles of New and Emerging HER2-, HER3-, and TROP2-Targeting Agents in NSCLC

• Delving Into the Data: Expert Discussions on the Latest Findings on HER2-, HER3-, and TROP2-Targeted Therapies
• Expert Perspectives on the Clinical Implications and Potential of Investigational Targeted Agents to Transform the Treatment of HER2-, HER3-, and TROP2-Altered NSCLC

Synthesis and Conclusions

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne, MD, PhD (USA)
Suresh S. Ramalingam, MD (USA)
Solange Peters, MD, PhD, (Switzerland)

Agenda

Welcome and Introduction (5 min)
Pasi Jänne, MD, PhD, USA
Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC (15 min)
Suresh S. Ramalingam, MD, USA
Targeting Checkpoint Inhibitor Resistance in NSCLC (15 min)
Solange Peters, MD, PhD, Switzerland
Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-driven NSCLC (15 min)
Pasi Jänne, MD, PhD, USA
Q & A (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Charu Aggarwal, MD, MPH (USA)
Stephen Liu, MD (USA)

Agenda
Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer (15 min) Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC (15 min) Applying National Cancer Center Network (NCCN) Guidelines to Practice (15 min) Conclusions (5 min) Questions and Answers (10 min)

IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Date: Wednesday, September 8, 2021 | Time: 14:00 – 15:00 EDT

View Program / Invitation (PDF)

Chairs/Speakers:

Tony Mok, MD, FRCPC, FASCO (HK)
Shirish Gadgeel, MD (USA)
Antonio Passaro, MD, PhD (Italy)

Agenda
Welcome and Introductions (5 min) Prof. Tony S.K. Mok (Chair) EGFR Insertion Mutations in NSCLC: Why and How Do We Test? (15 min) Dr. Shirish M. Gadgeel New and Emerging Therapies for NSCLC with EXON 20 INS Mutations (20 min) Prof. Tony S.K. Mok (Chair) Managing Toxicity with Anti-EGFR Exon 20 Agents (10 min) Dr. Antonio Passaro Audience Q&A and Closing Remarks (10 min) All Faculty

IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs’

Date: Thursday, September 9, 2021 | Time: 07:15 - 08:15 EDT

View Program / Invitation (PDF)

Chairs/Speakers:

Yi-Long Wu, MD (China)
Suresh Senan, MRCP, FRCR, PhD (The Netherlands)
Zhijie Wang (China)

Agenda
Welcome and Introduction (5 min) Yi-Long Wu Clinical data with immuno-oncology for unresectable Stage III NSCLC (15 min) Suresh Senan Translating the clinical benefits of EGFR-TKIs across EGFRm NSCLC (15 min) Zhijie Wang Panel discussion: Survivorship in NSCLC (25 min) All/Panel(Chaired by Yi-Long Wu)

IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape With Novel Strategies

Date: Thursday, September 9, 2021 | Time: 15:15 - 16:15 EDT

View Program / Invitation (PDF)

Chairs/Speakers:

David R. Gandara (USA)
Alexander I Spira, MD, PhD, FACP (USA)
Afshin N. Dowlati, MD (USA)

Agenda
Welcome and Introductions (5 min) David R. Gandara The Evolving Biomarker Landscape in Advanced NSCLC (15 min) David R. Gandara KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC (15 min) Alexander I. Spira Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC (15 min) Afshin Dowlati Discussion All Faculty

View Program / Invitation (PDF)

Speaker:

Eric Nadler, MD, MPP (USA)

Agenda
An overview of unmet needs in SCLC Eric Nadler Current treatment guidelines for SCLC Eric Nadler Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Eric Nadler Considerations for dosing, administration, and patient counseling Eric Nadler

IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Date: Thursday, September 9, 2021 | Time: 15:15 - 16:15 EDT

View Program / Invitation (PDF)

Chairs/Speakers:

Roy Herbst, MD, PhD (USA)
Sarah Goldberg, MD, MPH (USA)
Aleš Ryška, MUDr, PhD (Czech Republic)

Agenda
Introduction (5 min) Roy Herbst, MD, PhD, USA Key Concepts in NSCLC Biomarker Testing (15 min) Aleš Ryška, MUDr, PhD, Czech Republic Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC (20 min) Roy Herbst, MD, PhD, USA IRAE Considerations for Patients with NSCLC Receiving Immunotherapy (10 min) Sarah Goldberg, MD, MPH, USA Q&A Session (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Mark Socinski, MD (USA)
Silvia Novello, MD, PhD (Italy)
Nobuyuki Takakura, MD, PhD (Japan)
Myung- Ju Ahn, MD (South Korea)

Agenda

Welcome and introduction (5 min)
Chair – Mark Socinski, USA
Is a one size fits all approach still appropriate for NSCLC with an EGFR mutation, are all mutations equal? (15 min)
Silvia Novello, Italy
Scientific rationale for dual inhibition of VEGF and EGFR (10 min)
Nobuyuki Takakura, Japan
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (10 min)
Myung-Ju Ahn, Korea
Panel discussion and Q&A (15 min)
Symposium closing remarks (5 min)
Chair – Mark Socinski, USA

View Program / Invitation (PDF)

Chairs/Speakers:

Joshua Sabari, MD (USA)
Ticiana A. Leal, MD (USA)
Chris Manley, MD (USA)

Agenda
Welcome and introductions Joshua Sabari, MD (USA) EGFR mutated NSCLC – Progress, Recent Developments, and Unmet Needs Ticiana A. Leal, MD, USA Advances in early diagnosis, detection and intervention of lung cancer Chris Manley, MD, USA Discussion/Q&A

View Program / Invitation (PDF)

Chairs/Speakers:

D Ross Camidge, MD, PhD (USA)
Justin F Gainor, MD (USA)
Alexander E Drilon, MD (USA)
Neil Love, MD (USA)

Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?

Date: Sunday, September 12, 2021 | Time: 23:15 – 00:15 EDT

View Program / Invitation (PDF)

Chairs/Speakers:

Zofia Piotrowska, MD (USA)
Joshua Sabari, MD (USA)
Maureen Zakowski, MD, JD (USA)

Agenda
Introduction Zofia Piotrowska, MD Key Questions for Practice: Optimizing the Diagnosis and Management of Patients With NSCLC and Molecular Alterations Zofia Piotrowska, MD Joshua Sabari, MD Maureen Zakowski, MD, JD Conclusions and Q&A Zofia Piotrowska, MD Backstage Pass Breakout Session (Optional)

View Program / Invitation (PDF)

Chairs/Speakers:

Edward B Garon, MD, MS (USA)
Harvey I Pass, MD (USA)
Heather Wakelee, MD (USA)
Neil Love, MD (USA)

Agenda
Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

Date: Monday, September 13, 2021 | Time: 18:15 – 19:15 EDT

View Program / Invitation (PDF)

Chairs/Speakers:

Luis Paz-Ares, MD, PhD (Spain)
Corey Langer, MD (USA)
Keunchil Park, MD PhD (South Korea)
Marina Garassino, MBBS (Italy)

Agenda
Disease Landscape Overview (15 min) Luis Paz-Ares, MD, PhD, Spain Pathobiology and Molecular Profile of ADC targets in NSCLC (10 min) Corey Langer, MD, USA ADCs Targeting the HER Family and Clinical Data in NSCLC (10 min) Keunchil Park, MD PhD, South Korea Emerging ADC Targets and Clinical Data in NSCLC (10 min) Marina Garassino, MBBS, Italy Faculty Panel: Live Q&A (15 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Julie R. Brahmer, MD (USA)
Jarushka Naidoo, MB BCH BAO, MHS (USA)

Agenda

Welcome and Introduction (5 min)
Overview of Immunotherapy in Nonmetastatic NSCLC (15 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Current immunotherapy landscape in advanced NSCLC
• New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC (25 min)

Julie R. Brahmer, MD, USA

• Current immunotherapy landscape in advanced NSCLC

• Immune resistance and sequencing of therapy

• Emerging biomarkers of response to ICI therapy in NSCLC
Immunotherapy in Advanced or Metastatic NSCLC: Special Populations (10 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Response to ICI-based therapy in patients with cachexia
• ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation
Final Panel Discussion and Audience Question and Answer Session (5 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Edgardo Santos, MD, FACP (USA)
Snehal Thakkar, MD (USA)
Lisa Macera, PhD (USA)

Agenda
Welcome & Introduction (5 min) Edgardo Santos Growing Importance of Genomic Profiling (15 min) Snehal Thakkar Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection (15 min) Lisa Macera NSCLC Case Studies (15 min) Snehal Thakkar, Edgardo Santos Q&A (10 min) All Faculty

View Program / Invitation (PDF)

Chairs/Speakers:

Melissa L. Johnson, MD (USA)
Helena Yu, MD (USA)
Benjamin Levy, MD (USA)

Agenda

Welcome and Introduction
MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient

Clinical Accelerator: Translating Science, Transforming Practice

• Profiles of New and Emerging HER2-, HER3-, and TROP2-Targeting Agents in NSCLC

• Delving Into the Data: Expert Discussions on the Latest Findings on HER2-, HER3-, and TROP2-Targeted Therapies
• Expert Perspectives on the Clinical Implications and Potential of Investigational Targeted Agents to Transform the Treatment of HER2-, HER3-, and TROP2-Altered NSCLC

Synthesis and Conclusions

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne, MD, PhD (USA)
Suresh S. Ramalingam, MD (USA)
Solange Peters, MD, PhD, (Switzerland)

Agenda

Welcome and Introduction (5 min)
Pasi Jänne, MD, PhD, USA
Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC (15 min)
Suresh S. Ramalingam, MD, USA
Targeting Checkpoint Inhibitor Resistance in NSCLC (15 min)
Solange Peters, MD, PhD, Switzerland
Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-driven NSCLC (15 min)
Pasi Jänne, MD, PhD, USA
Q & A (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Charu Aggarwal, MD, MPH (USA)
Stephen Liu, MD (USA)

Agenda
Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer (15 min) Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC (15 min) Applying National Cancer Center Network (NCCN) Guidelines to Practice (15 min) Conclusions (5 min) Questions and Answers (10 min)

IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Date: Wednesday, September 8, 2021 | Time: 20:00 – 21:00 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

Tony Mok, MD, FRCPC, FASCO (HK)
Shirish Gadgeel, MD (USA)
Antonio Passaro, MD, PhD (Italy)

Agenda
Welcome and Introductions (5 min) Prof. Tony S.K. Mok (Chair) EGFR Insertion Mutations in NSCLC: Why and How Do We Test? (15 min) Dr. Shirish M. Gadgeel New and Emerging Therapies for NSCLC with EXON 20 INS Mutations (20 min) Prof. Tony S.K. Mok (Chair) Managing Toxicity with Anti-EGFR Exon 20 Agents (10 min) Dr. Antonio Passaro Audience Q&A and Closing Remarks (10 min) All Faculty

IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs’

Date: Thursday, September 9, 2021 | Time: 13:15 - 14:15 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

Yi-Long Wu, MD (China)
Suresh Senan, MRCP, FRCR, PhD (The Netherlands)
Zhijie Wang (China)

Agenda
Welcome and Introduction (5 min) Yi-Long Wu Clinical data with immuno-oncology for unresectable Stage III NSCLC (15 min) Suresh Senan Translating the clinical benefits of EGFR-TKIs across EGFRm NSCLC (15 min) Zhijie Wang Panel discussion: Survivorship in NSCLC (25 min) All/Panel(Chaired by Yi-Long Wu)

IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape With Novel Strategies

Date: Thursday, September 9, 2021 | Time: 21:15 - 22:15 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

David R. Gandara (USA)
Alexander I Spira, MD, PhD, FACP (USA)
Afshin N. Dowlati, MD (USA)

Agenda
Welcome and Introductions (5 min) David R. Gandara The Evolving Biomarker Landscape in Advanced NSCLC (15 min) David R. Gandara KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC (15 min) Alexander I. Spira Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC (15 min) Afshin Dowlati Discussion All Faculty

View Program / Invitation (PDF)

Speaker:

Eric Nadler, MD, MPP (USA)

Agenda
An overview of unmet needs in SCLC Eric Nadler Current treatment guidelines for SCLC Eric Nadler Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Eric Nadler Considerations for dosing, administration, and patient counseling Eric Nadler

IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Date: Thursday, September 9, 2021 | Time: 21:15 - 22:15 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

Roy Herbst, MD, PhD (USA)
Sarah Goldberg, MD, MPH (USA)
Aleš Ryška, MUDr, PhD (Czech Republic)

Agenda
Introduction (5 min) Roy Herbst, MD, PhD, USA Key Concepts in NSCLC Biomarker Testing (15 min) Aleš Ryška, MUDr, PhD, Czech Republic Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC (20 min) Roy Herbst, MD, PhD, USA IRAE Considerations for Patients with NSCLC Receiving Immunotherapy (10 min) Sarah Goldberg, MD, MPH, USA Q&A Session (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Mark Socinski, MD (USA)
Silvia Novello, MD, PhD (Italy)
Nobuyuki Takakura, MD, PhD (Japan)
Myung- Ju Ahn, MD (South Korea)

Agenda

Welcome and introduction (5 min)
Chair – Mark Socinski, USA
Is a one size fits all approach still appropriate for NSCLC with an EGFR mutation, are all mutations equal? (15 min)
Silvia Novello, Italy
Scientific rationale for dual inhibition of VEGF and EGFR (10 min)
Nobuyuki Takakura, Japan
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (10 min)
Myung-Ju Ahn, Korea
Panel discussion and Q&A (15 min)
Symposium closing remarks (5 min)
Chair – Mark Socinski, USA

View Program / Invitation (PDF)

Chairs/Speakers:

Joshua Sabari, MD (USA)
Ticiana A. Leal, MD (USA)
Chris Manley, MD (USA)

Agenda
Welcome and introductions Joshua Sabari, MD (USA) EGFR mutated NSCLC – Progress, Recent Developments, and Unmet Needs Ticiana A. Leal, MD, USA Advances in early diagnosis, detection and intervention of lung cancer Chris Manley, MD, USA Discussion/Q&A

View Program / Invitation (PDF)

Chairs/Speakers:

D Ross Camidge, MD, PhD (USA)
Justin F Gainor, MD (USA)
Alexander E Drilon, MD (USA)
Neil Love, MD (USA)

Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?

Date: Monday, September 13, 2021 | Time: 05:15 – 06:15 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

Zofia Piotrowska, MD (USA)
Joshua Sabari, MD (USA)
Maureen Zakowski, MD, JD (USA)

Agenda
Introduction Zofia Piotrowska, MD Key Questions for Practice: Optimizing the Diagnosis and Management of Patients With NSCLC and Molecular Alterations Zofia Piotrowska, MD Joshua Sabari, MD Maureen Zakowski, MD, JD Conclusions and Q&A Zofia Piotrowska, MD Backstage Pass Breakout Session (Optional)

IS12 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Early-Stage Non-Small Cell Lung Cancer

Date: Monday, September 13, 2021 | Time: 05:15 – 06:15 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

Edward B Garon, MD, MS (USA)
Harvey I Pass, MD (USA)
Heather Wakelee, MD (USA)
Neil Love, MD (USA)

Agenda
Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

Date: Tuesday, September 14, 2021 | Time: 00:15 – 1:15 CEST

View Program / Invitation (PDF)

Chairs/Speakers:

Luis Paz-Ares, MD, PhD (Spain)
Corey Langer, MD (USA)
Keunchil Park, MD PhD (South Korea)
Marina Garassino, MBBS (Italy)

Agenda
Disease Landscape Overview (15 min) Luis Paz-Ares, MD, PhD, Spain Pathobiology and Molecular Profile of ADC targets in NSCLC (10 min) Corey Langer, MD, USA ADCs Targeting the HER Family and Clinical Data in NSCLC (10 min) Keunchil Park, MD PhD, South Korea Emerging ADC Targets and Clinical Data in NSCLC (10 min) Marina Garassino, MBBS, Italy Faculty Panel: Live Q&A (15 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Julie R. Brahmer, MD (USA)
Jarushka Naidoo, MB BCH BAO, MHS (USA)

Agenda

Welcome and Introduction (5 min)
Overview of Immunotherapy in Nonmetastatic NSCLC (15 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Current immunotherapy landscape in advanced NSCLC
• New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC (25 min)

Julie R. Brahmer, MD, USA

• Current immunotherapy landscape in advanced NSCLC

• Immune resistance and sequencing of therapy

• Emerging biomarkers of response to ICI therapy in NSCLC
Immunotherapy in Advanced or Metastatic NSCLC: Special Populations (10 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Response to ICI-based therapy in patients with cachexia
• ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation
Final Panel Discussion and Audience Question and Answer Session (5 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Edgardo Santos, MD, FACP (USA)
Snehal Thakkar, MD (USA)
Lisa Macera, PhD (USA)

Agenda
Welcome & Introduction (5 min) Edgardo Santos Growing Importance of Genomic Profiling (15 min) Snehal Thakkar Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection (15 min) Lisa Macera NSCLC Case Studies (15 min) Snehal Thakkar, Edgardo Santos Q&A (10 min) All Faculty

View Program / Invitation (PDF)

Chairs/Speakers:

Melissa L. Johnson, MD (USA)
Helena Yu, MD (USA)
Benjamin Levy, MD (USA)

Agenda

Welcome and Introduction
MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient

Clinical Accelerator: Translating Science, Transforming Practice

• Profiles of New and Emerging HER2-, HER3-, and TROP2-Targeting Agents in NSCLC

• Delving Into the Data: Expert Discussions on the Latest Findings on HER2-, HER3-, and TROP2-Targeted Therapies
• Expert Perspectives on the Clinical Implications and Potential of Investigational Targeted Agents to Transform the Treatment of HER2-, HER3-, and TROP2-Altered NSCLC

Synthesis and Conclusions

IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC

Date: Thursday, September 9, 2021 | Time: 02:00 – 03:00 SGT

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne, MD, PhD (USA)
Suresh S. Ramalingam, MD (USA)
Solange Peters, MD, PhD, (Switzerland)

Agenda

Welcome and Introduction (5 min)
Pasi Jänne, MD, PhD, USA
Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC (15 min)
Suresh S. Ramalingam, MD, USA
Targeting Checkpoint Inhibitor Resistance in NSCLC (15 min)
Solange Peters, MD, PhD, Switzerland
Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-driven NSCLC (15 min)
Pasi Jänne, MD, PhD, USA
Q & A (10 min)

IS02 - Satellite CME Symposium by Med Learning Group: A New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View

Date: Thursday, September 9, 2021 | Time: 02:00 – 03:00 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Charu Aggarwal, MD, MPH (USA)
Stephen Liu, MD (USA)

Agenda
Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer (15 min) Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC (15 min) Applying National Cancer Center Network (NCCN) Guidelines to Practice (15 min) Conclusions (5 min) Questions and Answers (10 min)

IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Date: Thursday, September 9, 2021 | Time: 02:00 – 03:00 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Tony Mok, MD, FRCPC, FASCO (HK)
Shirish Gadgeel, MD (USA)
Antonio Passaro, MD, PhD (Italy)

Agenda
Welcome and Introductions (5 min) Prof. Tony S.K. Mok (Chair) EGFR Insertion Mutations in NSCLC: Why and How Do We Test? (15 min) Dr. Shirish M. Gadgeel New and Emerging Therapies for NSCLC with EXON 20 INS Mutations (20 min) Prof. Tony S.K. Mok (Chair) Managing Toxicity with Anti-EGFR Exon 20 Agents (10 min) Dr. Antonio Passaro Audience Q&A and Closing Remarks (10 min) All Faculty

IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs’

Date: Thursday, September 9, 2021 | Time: 19:15 - 20:15 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Yi-Long Wu, MD (China)
Suresh Senan, MRCP, FRCR, PhD (The Netherlands)
Zhijie Wang (China)

Agenda
Welcome and Introduction (5 min) Yi-Long Wu Clinical data with immuno-oncology for unresectable Stage III NSCLC (15 min) Suresh Senan Translating the clinical benefits of EGFR-TKIs across EGFRm NSCLC (15 min) Zhijie Wang Panel discussion: Survivorship in NSCLC (25 min) All/Panel(Chaired by Yi-Long Wu)

IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape With Novel Strategies

Date: Friday, September 10, 2021 | Time: 03:15 - 04:15 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

David R. Gandara (USA)
Alexander I Spira, MD, PhD, FACP (USA)
Afshin N. Dowlati, MD (USA)

Agenda
Welcome and Introductions (5 min) David R. Gandara The Evolving Biomarker Landscape in Advanced NSCLC (15 min) David R. Gandara KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC (15 min) Alexander I. Spira Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC (15 min) Afshin Dowlati Discussion All Faculty

IS06 - Industry Symposium Sponsored by Jazz Pharmaceuticals: Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC)

Date: Friday, September 10, 2021 | Time: 03:15 - 04:15 SGT

View Program / Invitation (PDF)

Speaker:

Eric Nadler, MD, MPP (USA)

Agenda
An overview of unmet needs in SCLC Eric Nadler Current treatment guidelines for SCLC Eric Nadler Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Eric Nadler Considerations for dosing, administration, and patient counseling Eric Nadler

IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Date: Friday, September 10, 2021 | Time: 03:15 - 04:15 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Roy Herbst, MD, PhD (USA)
Sarah Goldberg, MD, MPH (USA)
Aleš Ryška, MUDr, PhD (Czech Republic)

Agenda
Introduction (5 min) Roy Herbst, MD, PhD, USA Key Concepts in NSCLC Biomarker Testing (15 min) Aleš Ryška, MUDr, PhD, Czech Republic Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC (20 min) Roy Herbst, MD, PhD, USA IRAE Considerations for Patients with NSCLC Receiving Immunotherapy (10 min) Sarah Goldberg, MD, MPH, USA Q&A Session (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Mark Socinski, MD (USA)
Silvia Novello, MD, PhD (Italy)
Nobuyuki Takakura, MD, PhD (Japan)
Myung- Ju Ahn, MD (South Korea)

Agenda

Welcome and introduction (5 min)
Chair – Mark Socinski, USA
Is a one size fits all approach still appropriate for NSCLC with an EGFR mutation, are all mutations equal? (15 min)
Silvia Novello, Italy
Scientific rationale for dual inhibition of VEGF and EGFR (10 min)
Nobuyuki Takakura, Japan
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (10 min)
Myung-Ju Ahn, Korea
Panel discussion and Q&A (15 min)
Symposium closing remarks (5 min)
Chair – Mark Socinski, USA

View Program / Invitation (PDF)

Chairs/Speakers:

Joshua Sabari, MD (USA)
Ticiana A. Leal, MD (USA)
Chris Manley, MD (USA)

Agenda
Welcome and introductions Joshua Sabari, MD (USA) EGFR mutated NSCLC – Progress, Recent Developments, and Unmet Needs Ticiana A. Leal, MD, USA Advances in early diagnosis, detection and intervention of lung cancer Chris Manley, MD, USA Discussion/Q&A

View Program / Invitation (PDF)

Chairs/Speakers:

D Ross Camidge, MD, PhD (USA)
Justin F Gainor, MD (USA)
Alexander E Drilon, MD (USA)
Neil Love, MD (USA)

Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?

Date: Monday, September 13, 2021 | Time: 11:15 – 12:15 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Zofia Piotrowska, MD (USA)
Joshua Sabari, MD (USA)
Maureen Zakowski, MD, JD (USA)

Agenda
Introduction Zofia Piotrowska, MD Key Questions for Practice: Optimizing the Diagnosis and Management of Patients With NSCLC and Molecular Alterations Zofia Piotrowska, MD Joshua Sabari, MD Maureen Zakowski, MD, JD Conclusions and Q&A Zofia Piotrowska, MD Backstage Pass Breakout Session (Optional)

IS12 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Early-Stage Non-Small Cell Lung Cancer

Date: Monday, September 13, 2021 | Time: 11:15 – 12:15 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Edward B Garon, MD, MS (USA)
Harvey I Pass, MD (USA)
Heather Wakelee, MD (USA)
Neil Love, MD (USA)

Agenda
Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

Date: Tuesday, September 14, 2021 | Time: 06:15 – 07:15 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Luis Paz-Ares, MD, PhD (Spain)
Corey Langer, MD (USA)
Keunchil Park, MD PhD (South Korea)
Marina Garassino, MBBS (Italy)

Agenda
Disease Landscape Overview (15 min) Luis Paz-Ares, MD, PhD, Spain Pathobiology and Molecular Profile of ADC targets in NSCLC (10 min) Corey Langer, MD, USA ADCs Targeting the HER Family and Clinical Data in NSCLC (10 min) Keunchil Park, MD PhD, South Korea Emerging ADC Targets and Clinical Data in NSCLC (10 min) Marina Garassino, MBBS, Italy Faculty Panel: Live Q&A (15 min)

IS15 - Satellite CME Symposium by Clinical Care Options: Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

Date: Wednesday, September 15, 2021 | Time: 05:00 – 06:00 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Julie R. Brahmer, MD (USA)
Jarushka Naidoo, MB BCH BAO, MHS (USA)

Agenda

Welcome and Introduction (5 min)
Overview of Immunotherapy in Nonmetastatic NSCLC (15 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Current immunotherapy landscape in advanced NSCLC
• New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC (25 min)

Julie R. Brahmer, MD, USA

• Current immunotherapy landscape in advanced NSCLC

• Immune resistance and sequencing of therapy

• Emerging biomarkers of response to ICI therapy in NSCLC
Immunotherapy in Advanced or Metastatic NSCLC: Special Populations (10 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Response to ICI-based therapy in patients with cachexia
• ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation
Final Panel Discussion and Audience Question and Answer Session (5 min)

IS16 - Industry Symposium Sponsored by Exact Sciences: What Can We Learn from NSCLC? Using Comprehensive Genomic Profiling to Enhance Patient Care

Date: Wednesday, September 15, 2021 | Time: 05:00 – 06:00 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Edgardo Santos, MD, FACP (USA)
Snehal Thakkar, MD (USA)
Lisa Macera, PhD (USA)

Agenda
Welcome & Introduction (5 min) Edgardo Santos Growing Importance of Genomic Profiling (15 min) Snehal Thakkar Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection (15 min) Lisa Macera NSCLC Case Studies (15 min) Snehal Thakkar, Edgardo Santos Q&A (10 min) All Faculty

IS17 - Satellite CME Symposium by PeerView Institute for Medical Education: Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapy to Address Unmet Needs in Advanced NSCLC

Date: Wednesday, September 15, 2021 | Time: 05:00 – 06:00 SGT

View Program / Invitation (PDF)

Chairs/Speakers:

Melissa L. Johnson, MD (USA)
Helena Yu, MD (USA)
Benjamin Levy, MD (USA)

Agenda

Welcome and Introduction
MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient

Clinical Accelerator: Translating Science, Transforming Practice

• Profiles of New and Emerging HER2-, HER3-, and TROP2-Targeting Agents in NSCLC

• Delving Into the Data: Expert Discussions on the Latest Findings on HER2-, HER3-, and TROP2-Targeted Therapies
• Expert Perspectives on the Clinical Implications and Potential of Investigational Targeted Agents to Transform the Treatment of HER2-, HER3-, and TROP2-Altered NSCLC

Synthesis and Conclusions

IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC

Date: Thursday, September 9, 2021 | Time: 04:00 – 05:00 AEST

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne, MD, PhD (USA)
Suresh S. Ramalingam, MD (USA)
Solange Peters, MD, PhD, (Switzerland)

Agenda

Welcome and Introduction (5 min)
Pasi Jänne, MD, PhD, USA
Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC (15 min)
Suresh S. Ramalingam, MD, USA
Targeting Checkpoint Inhibitor Resistance in NSCLC (15 min)
Solange Peters, MD, PhD, Switzerland
Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-driven NSCLC (15 min)
Pasi Jänne, MD, PhD, USA
Q & A (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Charu Aggarwal, MD, MPH (USA)
Stephen Liu, MD (USA)

Agenda
Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer (15 min) Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC (15 min) Applying National Cancer Center Network (NCCN) Guidelines to Practice (15 min) Conclusions (5 min) Questions and Answers (10 min)

IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Date: Thursday, September 9, 2021 | Time: 04:00 – 05:00 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Tony Mok, MD, FRCPC, FASCO (HK)
Shirish Gadgeel, MD (USA)
Antonio Passaro, MD, PhD (Italy)

Agenda
Welcome and Introductions (5 min) Prof. Tony S.K. Mok (Chair) EGFR Insertion Mutations in NSCLC: Why and How Do We Test? (15 min) Dr. Shirish M. Gadgeel New and Emerging Therapies for NSCLC with EXON 20 INS Mutations (20 min) Prof. Tony S.K. Mok (Chair) Managing Toxicity with Anti-EGFR Exon 20 Agents (10 min) Dr. Antonio Passaro Audience Q&A and Closing Remarks (10 min) All Faculty

IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the treatment journey in NSCLC with immuno-oncology and EGFR-TKIs’

Date: Thursday, September 9, 2021 | Time: 21:15 - 22:15 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Yi-Long Wu, MD (China)
Suresh Senan, MRCP, FRCR, PhD (The Netherlands)
Zhijie Wang (China)

Agenda
Welcome and Introduction (5 min) Yi-Long Wu Clinical data with immuno-oncology for unresectable Stage III NSCLC (15 min) Suresh Senan Translating the clinical benefits of EGFR-TKIs across EGFRm NSCLC (15 min) Zhijie Wang Panel discussion: Survivorship in NSCLC (25 min) All/Panel(Chaired by Yi-Long Wu)

IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape With Novel Strategies

Date: Friday, September 10, 2021 | Time: 05:15 - 06:15 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

David R. Gandara (USA)
Alexander I Spira, MD, PhD, FACP (USA)
Afshin N. Dowlati, MD (USA)

Agenda
Welcome and Introductions (5 min) David R. Gandara The Evolving Biomarker Landscape in Advanced NSCLC (15 min) David R. Gandara KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC (15 min) Alexander I. Spira Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC (15 min) Afshin Dowlati Discussion All Faculty

IS06 - Industry Symposium Sponsored by Jazz Pharmaceuticals: Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC)

Date: Friday, September 10, 2021 | Time: 05:15 - 06:15 AEST

View Program / Invitation (PDF)

Speaker:

Eric Nadler, MD, MPP (USA)

Agenda
An overview of unmet needs in SCLC Eric Nadler Current treatment guidelines for SCLC Eric Nadler Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Eric Nadler Considerations for dosing, administration, and patient counseling Eric Nadler

IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Date: Friday, September 10, 2021 | Time: 05:15 - 06:15 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Roy Herbst, MD, PhD (USA)
Sarah Goldberg, MD, MPH (USA)
Aleš Ryška, MUDr, PhD (Czech Republic)

Agenda
Introduction (5 min) Roy Herbst, MD, PhD, USA Key Concepts in NSCLC Biomarker Testing (15 min) Aleš Ryška, MUDr, PhD, Czech Republic Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC (20 min) Roy Herbst, MD, PhD, USA IRAE Considerations for Patients with NSCLC Receiving Immunotherapy (10 min) Sarah Goldberg, MD, MPH, USA Q&A Session (10 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Mark Socinski, MD (USA)
Silvia Novello, MD, PhD (Italy)
Nobuyuki Takakura, MD, PhD (Japan)
Myung- Ju Ahn, MD (South Korea)

Agenda

Welcome and introduction (5 min)
Chair – Mark Socinski, USA
Is a one size fits all approach still appropriate for NSCLC with an EGFR mutation, are all mutations equal? (15 min)
Silvia Novello, Italy
Scientific rationale for dual inhibition of VEGF and EGFR (10 min)
Nobuyuki Takakura, Japan
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (10 min)
Myung-Ju Ahn, Korea
Panel discussion and Q&A (15 min)
Symposium closing remarks (5 min)
Chair – Mark Socinski, USA

View Program / Invitation (PDF)

Chairs/Speakers:

Joshua Sabari, MD (USA)
Ticiana A. Leal, MD (USA)
Chris Manley, MD (USA)

Agenda
Welcome and introductions Joshua Sabari, MD (USA) EGFR mutated NSCLC – Progress, Recent Developments, and Unmet Needs Ticiana A. Leal, MD, USA Advances in early diagnosis, detection and intervention of lung cancer Chris Manley, MD, USA Discussion/Q&A

View Program / Invitation (PDF)

Chairs/Speakers:

D Ross Camidge, MD, PhD (USA)
Justin F Gainor, MD (USA)
Alexander E Drilon, MD (USA)
Neil Love, MD (USA)

Agenda
MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?

Date: Monday, September 13, 2021 | Time: 13:15 – 14:15 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Zofia Piotrowska, MD (USA)
Joshua Sabari, MD (USA)
Maureen Zakowski, MD, JD (USA)

Agenda
Introduction Zofia Piotrowska, MD Key Questions for Practice: Optimizing the Diagnosis and Management of Patients With NSCLC and Molecular Alterations Zofia Piotrowska, MD Joshua Sabari, MD Maureen Zakowski, MD, JD Conclusions and Q&A Zofia Piotrowska, MD Backstage Pass Breakout Session (Optional)

IS12 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Early-Stage Non-Small Cell Lung Cancer

Date: Monday, September 13, 2021 | Time: 13:15 – 14:15 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Edward B Garon, MD, MS (USA)
Harvey I Pass, MD (USA)
Heather Wakelee, MD (USA)
Neil Love, MD (USA)

Agenda
Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

Date: Tuesday, September 14, 2021 | Time: 08:15 – 09:15 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Luis Paz-Ares, MD, PhD (Spain)
Corey Langer, MD (USA)
Keunchil Park, MD PhD (South Korea)
Marina Garassino, MBBS (Italy)

Agenda
Disease Landscape Overview (15 min) Luis Paz-Ares, MD, PhD, Spain Pathobiology and Molecular Profile of ADC targets in NSCLC (10 min) Corey Langer, MD, USA ADCs Targeting the HER Family and Clinical Data in NSCLC (10 min) Keunchil Park, MD PhD, South Korea Emerging ADC Targets and Clinical Data in NSCLC (10 min) Marina Garassino, MBBS, Italy Faculty Panel: Live Q&A (15 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Julie R. Brahmer, MD (USA)
Jarushka Naidoo, MB BCH BAO, MHS (USA)

Agenda

Welcome and Introduction (5 min)
Overview of Immunotherapy in Nonmetastatic NSCLC (15 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Current immunotherapy landscape in advanced NSCLC
• New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC (25 min)

Julie R. Brahmer, MD, USA

• Current immunotherapy landscape in advanced NSCLC

• Immune resistance and sequencing of therapy

• Emerging biomarkers of response to ICI therapy in NSCLC
Immunotherapy in Advanced or Metastatic NSCLC: Special Populations (10 min)

Jarushka Naidoo, MB BCH BAO, MHS, USA

• Response to ICI-based therapy in patients with cachexia
• ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation
Final Panel Discussion and Audience Question and Answer Session (5 min)

View Program / Invitation (PDF)

Chairs/Speakers:

Edgardo Santos, MD, FACP (USA)
Snehal Thakkar, MD (USA)
Lisa Macera, PhD (USA)

Agenda
Welcome & Introduction (5 min) Edgardo Santos Growing Importance of Genomic Profiling (15 min) Snehal Thakkar Oncotype MAP™ Pan-Cancer Tissue Test: Rapid Comprehensive Genomic Profiling to Aid in Therapy Selection (15 min) Lisa Macera NSCLC Case Studies (15 min) Snehal Thakkar, Edgardo Santos Q&A (10 min) All Faculty

IS17 - Satellite CME Symposium by PeerView Institute for Medical Education: Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapy to Address Unmet Needs in Advanced NSCLC

Date: Wednesday, September 15, 2021 | Time: 07:00 – 08:00 AEST

View Program / Invitation (PDF)

Chairs/Speakers:

Melissa L. Johnson, MD (USA)
Helena Yu, MD (USA)
Benjamin Levy, MD (USA)

Agenda

Welcome and Introduction
MasterClass: Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient

Clinical Accelerator: Translating Science, Transforming Practice

• Profiles of New and Emerging HER2-, HER3-, and TROP2-Targeting Agents in NSCLC

• Delving Into the Data: Expert Discussions on the Latest Findings on HER2-, HER3-, and TROP2-Targeted Therapies
• Expert Perspectives on the Clinical Implications and Potential of Investigational Targeted Agents to Transform the Treatment of HER2-, HER3-, and TROP2-Altered NSCLC

Synthesis and Conclusions

INDUSTRY SPONSORED SYMPOSIA AND SATELLITE CME SYMPOSIA

Contact

Stay Connected